Check out this upcoming #ATORG event on #MRD in lung cancer. Join us at 2pm HKT/SGT this coming Friday! #LCSM @iaslc.bsky.social @apoddc @APCLC_2023

Excited to be in Singapore for @ascocancer.bsky.social Breakthrough with @herbloongmd.bsky.social Naoto Ueno, Beth Mittendorf, and Rebecca Dent!

Quick 24hrs #whirlwind trip to #Shanghai 🇨🇳🥟🍜 to meet with #lungcancer colleagues 🫁 and friends. Always amazed by the amount and balance of #dynamism and #heritage of the city. #LCSM #drugdevelopment #collaborations

#Throwback to 1+ weeks' ago in #Chicago for the @oncodaily.bsky.social y #YvonneAwards26 for #Leadership. I am very grateful to all my #friends, #colleagues, #collaborators, #mentors & #family for supporting me through this journey. Thanks again! 🙏🙏🙏 @cuhkmedicine.bsky.social @iaslc.bsky.social

T-67 days before @ascocancer.bsky.social #ASCO26! I am looking forward to the largest oncology event of the year and specifically to the multiple #globaloncology sessions 🌐scheduled throughout the meeting. See you all in #Chicago where you get to experience all these 🌞🍃🌧️ within a day! 😄

Great to hear Dr @herbloongmd.bsky.social speak about immunotherapy clinical trials at Apollo Proton Cancer Centre in Chennai, India.

Putting some last minute slides together 😂. Flight delayed from #HKG to #FRA so not sure whether we can make the transit, but #GütenMorgenAlles and see you in person at Berlin for @myESMO #ESMO25! #sarcoma #LCSM @ctosociety @apoddc @APCLC_2023

Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025

The @ascocancer.bsky.social #InternationalAffairsCommittee #2025-26. An absolute delight and pleasure working with these highly engaged professionals from across the world 🌎 and across oncology disciplines. #BestASCOCommittee

It's always a pleasure meeting #colleagues on home turf in #hongkong 🇭🇰 after a long day of clinic. #LCSM @cuhkmedicine.bsky.social

Whirlwind 2 days in #Manila at #PSMO @astra-zeneca.bsky.social 🫁 #lungcancer #preceptorship w/ colleagues & experts including @KSamalaMD #ArthurLui 🇵🇭 together w/ #QuincyChu of @AlbertaUni 🇨🇦. Covered broad topics: #targetedtherapies, #IO, #EGFR and #SCLC. #LCSM @cuhkmedicine.bsky.social @APCLC_2023

Enhancing cost-effectiveness considerations in the adoption of new drugs in Hong Kong www.hkmj.org/abstracts/v3...

#ImprovingAccess to #effectivetherapies is mandate all physicians should uphold. How to incorporate these whilst balancing societal costs require guidelines & discussions. Our position paper on "Enhancing cost-effectiveness considerations in adoption of new drugs in HK" www.hkmj.org/earlyrelease...

The Strong International Camaraderie Between Past and Present Fellows of the PMH Fellowship - Herbert Loong @herbloongmd.bsky.social @pmresearch-uhn.bsky.social oncodaily.com/blog/herbert... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PMHFellowship

Herbert Loong: The Strong International Camaraderie Between Past and Present Fellows of the PMH Fellowship - OncoDaily

Herbert Loong: The Strong International Camaraderie Between Past and Present Fellows of the PMH Fellowship / Abdul Razak, Albiruni Ryan, cancer, Herbert

oncodaily.com

🇭🇰🚝✈️🇨🇦🚗🏥=🤩 Looking forward to #returning to #Toronto & my alma mater @uhnresearch.ca #PrincessMargaretCancerCentre for a short visit this weekend! Very honoured and privileged to be able to give #GrandRounds 🎙️ Best way to fight jetlag! See you soon!👋 #LCSM #Sarcoma #CUHKSarcoma #precisiononcology

Putting final touches together to my talk😀. Looking forward to welcoming you all to #hongkong 🇭🇰 for #ESMOTATAsia25! Don't be shy - come by and say hi! #drugdevelopment @cuhkmedicine.bsky.social @apoddc @APCLC_2023

#PublicEducation on #sarcomas can be fun! 😃 #facialkexpressions #CannotHideHit #HappyMonday #CUHKSarcoma youtu.be/XesQlcQPMOY?...

One week until the inaugural #ESMOTATAsia25 🤩 I'm looking forward to joining global drug development experts in🍜🇭🇰 + sharing insights on dose optimisation of novel combinations 🗓️ Saturday 19 July 2pm. @myesmo.bsky.social @herbloongmd.bsky.social @anmwongnz.bsky.social

Incorporating high-risk individuals beyond smoking history into lung cancer screening in Hong Kong: a cost-effectiveness study - JTO Clinical and Research Reports www.jtocrr.org/article/S266...

Thanks @liferaftgroup.bsky.social for opportunity to share some key #GIST updates from #ASCO25 w/ wider patients' community 🌎 through this webinar last week. @srothschild @cuhkmedicine.bsky.social @GISTNetwork @ctosociety #DrugDevelopment #sarcomas #CUHKSarcoma youtu.be/uoZULT8YlPU?...

Updates from ASCO 2025 Annual Meeting

YouTube video by The Life Raft Group

youtu.be

Come join us in a couple of hours as we discuss several #abstracts related to #GISTs presented at #ASCO25! Registration is free! Register here: us02web.zoom.us/webinar/regi... @liferaftgroup.bsky.social @ctosociety #sarcoma @cuhkmedicine.bsky.social #CUHKSarcoma #PublicEducation

After serving on #MembershipCommittee, I look forward to returning to #CommunicationsCommittee @iaslc.bsky.social w/ #LCSM colleagues from around the World 🌐 to create #effective, #efficient & #robust channels of communications between our society & community. @CUHKMedicine @apoddc @APCLC_2023

Sevabertinib Induces Durable Response in Advanced HER2-Mutant NSCLC #lungcancer #NSCLC #ASCO25 @herbloongmd.bsky.social @ascocancer.bsky.social www.onclive.com/view/sevaber...

Sevabertinib Induces Durable Response in Advanced HER2-Mutant NSCLC

Treatment with the oral TKI showed promising responses among 2 subgroups of patients with advanced, HER2-mutant non–small cell lung cancer.

onclive.com

#Honoured and #humbled to have been awarded #FASCO at @ascocancer.bsky.social #ASCO25. My thanks to my friends and colleagues for your overwhelming support along the way 😊 #sarcoma #LCSM #InternationalAffairsCommittee #drugdevelopment #precisiononcology

T-13hrs 59mins before landing in #Chicago for @ascocancer.bsky.social #ASCO25! ✈️ full of oncology colleagues from 🇭🇰🇵🇭 and from 🇦🇺🦘🐨😀. What’s the combined H-index of this flight? 🧐 Looking fwd to days of #scientificexchanges and #interactivediscussions. Safe travels everyone! See you at McCormick!

As @ascocancer.bsky.social #ASCO25 is round the corner, so is the end of my #chair of #InternationalAffairsCommittee. Tks all my colleagues & friends from around the World 🌍 for continuous support. Time to pass torch 🔥 to Dr. Monica Malik who will continue to push our global agenda forward!

Come join us in #hongkong 🇭🇰 🍜🥟🥡 for the #inaugural @myesmo.bsky.social #ESMOTATAsia25 on July 18-20, 2025! We have assembled a #stellar group of #international #faculties and #experts in #drugdevelopment to help move the field forward. Register today!

Thanks to Dr Herbert Loong, of The Chinese University of Hong Kong, for speaking with us during #AACR25 about the efficacy of D3S-001 in KRAS G12C inhibitor–resistant NSCLC! See our site for more meeting insights! @theaacr.bsky.social #lcsm #oncology www.onclive.com/conference/a...

Thanks my #coinvestigators for opportunity to present data of #D3S_001, a novel #KRASG12C inhibitor in #G12Ci pre-treated #NSCLC at @theaacr.bsky.social #AACR25. Strong & rapid #targetengagement confer superior #efficacy c.f. 1st generation G12Ci. ✔️ORR 30%; DCR 80% in KRASG12Ci pre-treated popn.

Better late than never! 🤣 Arrived in #Chicago for @theaacr.bsky.social #AACR25 after 14 hours flight ✈️ and looking forward to the #ClinicalTrials #Minisymposium tomorrow.